Clinical Trial Update: Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) [Phase 2]

View source ↗

Summary

Phase 2 REPEAT trial evaluating repeated exposure to eltrombopag in adults with immune thrombocytopenia has completed and results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Purpura, Thrombocytopaenic, Idiopathic | Phase 2 | Status: COMPLETED | Results posted: 2009-08-11